Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Gross Profit (2021 - 2025)

Tg Therapeutics has reported Gross Profit over the past 5 years, most recently at $154.4 million for Q4 2025.

  • Quarterly results put Gross Profit at $154.4 million for Q4 2025, up 66.44% from a year ago — trailing twelve months through Dec 2025 was $515.6 million (up 77.47% YoY), and the annual figure for FY2025 was $515.6 million, up 77.47%.
  • Gross Profit for Q4 2025 was $154.4 million at Tg Therapeutics, up from $133.6 million in the prior quarter.
  • Over the last five years, Gross Profit for TGTX hit a ceiling of $162.3 million in Q3 2023 and a floor of $77000.0 in Q4 2022.
  • Median Gross Profit over the past 5 years was $65.2 million (2024), compared with a mean of $68.4 million.
  • Biggest five-year swings in Gross Profit: surged 176319.57% in 2023 and later crashed 54.08% in 2024.
  • Tg Therapeutics' Gross Profit stood at $654000.0 in 2021, then crashed by 88.23% to $77000.0 in 2022, then surged by 46805.19% to $36.1 million in 2023, then skyrocketed by 156.9% to $92.8 million in 2024, then soared by 66.44% to $154.4 million in 2025.
  • The last three reported values for Gross Profit were $154.4 million (Q4 2025), $133.6 million (Q3 2025), and $122.2 million (Q2 2025) per Business Quant data.